Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
21.90
-0.03 (-0.14%)
Dec 5, 2025, 4:00 PM EST - Market closed
Company Description
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC.
The company was incorporated in 2020 and is based in Palo Alto, California.
Evommune, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Nov 6, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Luis Pena |
Contact Details
Address: 1841 Page Mill Road, Suite 100 Palo Alto, California 94304 United States | |
| Phone | (925) 247-4487 |
| Website | evommune.com |
Stock Details
| Ticker Symbol | EVMN |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0002044725 |
| CUSIP Number | 30054Y107 |
| ISIN Number | US30054Y1073 |
| Employer ID | 85-0742575 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Luis Peña | President & Chief Executive Officer and Director |
| Kyle Carver, M.B.A., C.P.A. | Chief Financial Officer |
| Eugene A. Bauer, M.D. | Chief Medical Officer and Director |
| Gregory S. Moss, Esq. | Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Jeegar Patel, Ph.D. | Chief Scientific Officer |
| Janice Drew, M.P.H. | Executive Vice President, Operations |
| Benjamin F. McGraw, III, Pharma. D. | Director, Chairman of the Board |
| Francois Beaubien, Ph.D., C.F.A. | Director |
| David E. Cohen, M.D., M.P.H. | Director |
| Derek DiRocco, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 17, 2025 | SCHEDULE 13D | Filing |
| Nov 17, 2025 | SCHEDULE 13G | Filing |
| Nov 14, 2025 | SCHEDULE 13D | Filing |
| Nov 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 7, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 424B4 | Prospectus |
| Nov 6, 2025 | FWP | Free Writing Prospectus |
| Nov 5, 2025 | CERT | Certification by an exchange approving securities for listing |
| Nov 4, 2025 | 8-A12B | Registration of securities |
| Oct 30, 2025 | FWP | Free Writing Prospectus |